{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"groups":[{"description":"INDUCTION PHASE: Patients receive ofatumumab IV on days 1, 8, and 15 and bortezomib SC on days 8 and 15. Beginning on course 2, patients receive ofatumumab IV on days 1 and 15 and bortezomib SC on days 1, 8, and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.\n\nMAINTENANCE PHASE: Beginning 8 weeks after course 4 of induction phase, patients receive ofatumumab IV on day 1 and bortezomib SC on days 1, 8, and 15. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.\n\nofatumumab: Given IV\n\nbortezomib: Given SC\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (Monoclonal Antibody Therapy)"}],"populationDescription":"Due to the study's early termination and low accrual, data were not collected for this assessment.","reportingStatus":"POSTED","timeFrame":"From start of treatment to disease progression or death (regardless of the cause of death), whichever comes first, assessed up to 12 months","title":"Progression-free Survival","type":"SECONDARY"}